TY - JOUR AU - Bucher-Johannessen, Cecilie AU - Page, Christian M. AU - Haugen, Trine B. AU - Wojewodzic, Marcin W. AU - Fosså, Sophie D. AU - Grotmol, Tom AU - Haugnes, Hege S. AU - Rounge, Trine B. PY - 2019 DA - 2019/12/03 TI - Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome JO - Clinical Epigenetics SP - 179 VL - 11 IS - 1 AB - Cisplatin-based chemotherapy (CBCT) is part of standard treatment of several cancers. In testicular cancer (TC) survivors, an increased risk of developing metabolic syndrome (MetS) is observed. In this epigenome-wide association study, we investigated if CBCT relates to epigenetic changes (DNA methylation) and if epigenetic changes render individuals susceptible for developing MetS later in life. We analyzed methylation profiles, using the MethylationEPIC BeadChip, in samples collected ~ 16 years after treatment from 279 Norwegian TC survivors with known MetS status. Among the CBCT treated (n = 176) and non-treated (n = 103), 61 and 34 developed MetS, respectively. We used two linear regression models to identify if (i) CBCT results in epigenetic changes and (ii) epigenetic changes play a role in development of MetS. Then we investigated if these changes in (i) and (ii) links to genes, functional networks, and pathways related to MetS symptoms. SN - 1868-7083 UR - https://doi.org/10.1186/s13148-019-0764-4 DO - 10.1186/s13148-019-0764-4 ID - Bucher-Johannessen2019 ER -